A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT

We report a single-center phase I/II trial exploring the combination of everolimus (EVE) and mycophenolate mofetil (MMF) as calcineurin inhibitor (CNI)-free GVHD prophylaxis for 24 patients with hematologic malignancies and indication for allogeneic HCT after a high dose or reduced-intensity ablativ...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ann Hematol
Autori principali: Schäfer, Henning, Blümel-Lehmann, Jacqueline, Ihorst, Gabriele, Bertz, Hartmut, Wäsch, Ralph, Zeiser, Robert, Finke, Jürgen, Marks, Reinhard
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2021
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8285343/
https://ncbi.nlm.nih.gov/pubmed/33755792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-021-04487-y
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi